131379-34-5

Basic information

• Product Name: ETHYL 4'-CYANOBIPHENYL-3-CARBOXYLATE
• Synonyms: ETHYL 4'-CYANOBIPHENYL-3-CARBOXYLATE
• CAS NO: 131379-34-5
• Molecular Formula: C16H13NO2
• Molecular Weight: 251.28
• Mol File: 131379-34-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ETHYL 4'-CYANOBIPHENYL-3-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 4'-CYANOBIPHENYL-3-CARBOXYLATE(131379-34-5)
• EPA Substance Registry System: ETHYL 4'-CYANOBIPHENYL-3-CARBOXYLATE(131379-34-5)

Safety Data

• Hazardous Substances Data: 131379-34-5(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of the American Chemical Society, 114, p. 3983, 1992 DOI: 10.1021/ja00036a060

Upstream product

• 24398-88-7 ethyl 3-bromobenzoate 
• 623-00-7 4-bromobenzenecarbonitrile 
• 58313-23-8 3-iodobenzoic acid methyl ester 
• 4334-87-6 [3-(ethoxycarbonyl)phenyl]boronic acid 
• 1070663-96-5 ethyl 3-((methylsulfonyl)oxy)benzoate 
• 126747-14-6 4-cyanophenylboronic acid 
• 131379-14-1 4-cyanophenylzinc bromide 

Relevant articles and documents

Lead optimization and biological evaluation of fragment-based cN-II inhibitors

The development of cytosolic 5′-nucleotidase II (cN-II) inhibitors is essential to validate cN-II as a potential target for the reversion of resistance to cytotoxic nucleoside analogues. We previously reported a fragment-based approach combined with molecular modelling, herein, the selected hit-fragments were used again in another computational approach based on the Ilib-diverse (a software enabling to build virtual molecule libraries through fragment based de novo design) program to generate a focused library of potential inhibitors. A molecular scaffold related to a previously identified compound was selected and led to a novel series of compounds. Ten out of nineteen derivatives showed 50–75% inhibition on the purified recombinant protein at 200 μM and among them three derivatives (12, 13 and 18) exhibited Ki in the sub-millimolar range (0.84, 2.4 and 0.58 mM, respectively). Despite their only modest potency, the cN-II inhibitors showed synergistic effects when used in combination with cytotoxic purine nucleoside analogues on cancer cells. Therefore, these derivatives represent a family of non-nucleos(t)idic cN-II inhibitors with potential usefulness to overcome cancer drug resistance especially in hematological malignancies in which cN-II activity has been described as an important parameter.

Palladium catalyzed cross-couplings of organozincs in ionic liquids

Negishi cross-coupling reactions between aryl- or benzylzinc halides and various aryl iodides smoothly occur in ionic liquids in the presence of the new ionic phosphine ligand 2. This solvent allows a facile work-up and rapid cross-coupling reactions at r

Highly reactive forms of zinc and reagents thereof

A novel zerovalent zinc species and an organozinc reagent are disclosed. The zerovalent zinc species is directly produced by reaction of a reducing agent on a zinc salt, preferably Zn(CN)2. The organozinc reagent results from the reaction of the zerovalent zinc species and an organic compound having one or more stable anionic leaving groups. These organozinc reagents include a wide spectrum of functional groups in the organic radical, and are useful in a variety of reactions schemes.